HIV IN PATIENTS AND ANIMALS--CELL MEDIATED IMMUNITY AND VIRAL ISOLATION

我们继续与约翰·霍普金斯医疗中心合作研究 5 新患者参加了艾滋病毒骨髓移植研究。顺序 之前对这些艾滋病患者分离的 PBL 进行了病毒分离 以及骨髓移植后。培养患者细胞 与正常人类母细胞混合 4 周，每周取样并进行 HIV 检测 抗原。以下数据总结了截至 11/90 的结果， 表明病毒有减少的趋势 移植。该项目因重新评估而暂时停止 将由 DNA 病毒实验室的 Hana Golding 博士继续。 恒河猴接种后抗体和抗原状态的研究 1987年，活HIV-1病毒继续显示没有检测到抗原， 而抗体在两只血清反应呈阳性的动物中持续存在，尽管抗体水平较低 水平。还对 1988 年 9 月接种的一组恒河猴进行了追踪 在此财年期间，结果表明猴子接受了 gp160 重组痘苗病毒 IIIB 和 RF 病毒，然后进行 2 次加强接种 纯化的 gp160 在 95 周内保持血清阳性。后续研究 旨在评估是否接种 IIIB 重组痘苗和 在 2 个月和 8 个月时用纯化的 gp160 进行 2 次加强，间隔时间与 与第一个实验一起使用将重现或最大化 之前看到的回应。第 5 个月的血清评估 表明最初接种重组牛痘可诱导 比最初接种纯化的 gp160 具有更好的抗体反应。 这些动物的连续出血正在等待分析。 另一项研究测试了一种新的 IIIB gp160 重组体，与 之前的研究发现筛选时 6 个月内没有抗体反应 在标准 ELISA 上。 随后使用纯化的 gp160 ELISA 进行筛选 以及针对 IIIB、MN、SF2 V3 肽抗体的 ELISA 特异性 和 RF 菌株，表明一些动物的反应水平较低 两组均在第 4 个月时进行。

We continued collaboration with Johns Hopkins Medical Center studying 5 new patients enrolled in the HIV bone marrow transplant study. Sequential virus isolations were done on PBL isolated from these AIDS patients before and after bone marrow transplantation. The patients cells were cultured with normal human blast cells for 4 weeks, sampled weekly & tested for HIV antigen. The following data summarizes the results through 11/90, indicating that there is a trend towards virus reduction after transplantation. The project was temporarily halted for reevaluation and will be continued by Dr.Hana Golding in the Lab of DNA viruses. Studies of the antibody and antigen status of Rhesus monkeys inoculated in 1987 with live HIV-1 virus continued to reveal no antigen being detected, while antibody persisted in the 2 seropositive animals, though at lower levels. A group of Rhesus inoculated in Sept 1988 were also followed during this FY and results indicated that monkeys primed with a gp160 recombinant vaccinia to IIIB and RF viruses followed by 2 boosters with purified gp160 remained seropositive through 95 weeks. A followup study designed to evaluate whether inoculation of IIIB-recombinant vaccinia and 2 boosts with purified gp160 at 2 & 8 months, a different interval than used with the first experiment would either reproduce or maximize the response seen previously. Evaluation of sera through the 5th month indicated that initial inoculation with the vaccinia recombinant induced a better antibody response than initial inoculation with purified gp160. Sequential bleeds from these animals are awaiting analysis. Another study tested a new IIIB gp160 recombinant compared to that used in previous studies and found no antibody response in 6 months when screened on a standard ELISA. Subsequent screening using a purified gp160 ELISA as well as ELISA's specific for antibodies to V3 peptides of IIIB, MN, SF2 and RF strains, indicated low level responses in some of the animals in both groups by the 4th month.